Anna Maria Capelli
Overview
Explore the profile of Anna Maria Capelli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
221
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Giuliani M, Rizzi A, Pagano M, Raveglia L, Saccani F, Di Lascia M, et al.
ACS Med Chem Lett
. 2025 Feb;
16(2):317-326.
PMID: 39967626
Lysophosphatidic acid (LPA) is a phospholipid activating different biological functions by binding to G protein-coupled receptors (LPA). Among these, the role of the LPA receptor in modulating fibrotic processes is...
2.
Bruno P, Pala D, Micoli A, Corsi M, Accetta A, Carzaniga L, et al.
J Med Chem
. 2024 Dec;
68(3):2444-2465.
PMID: 39635891
The design of inhaled selective phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitors for the treatment of inflammatory lung diseases was pursued. Knowledge-based design of a novel isocoumarin scaffold that was able to...
3.
Pala D, Ronchi P, Rescigno D, Bertani B, Capelli A, Guariento S, et al.
ACS Med Chem Lett
. 2024 Nov;
15(11):1925-1932.
PMID: 39563792
ALK5 inhibitors represent an attractive therapeutic approach for the treatment of a variety of pathologies, including cancer and fibrosis. Herein, we report the design and characterization of a novel series...
4.
Bruno P, Micoli A, Corsi M, Pala D, Guariento S, Fiorelli C, et al.
J Med Chem
. 2024 Jun;
67(13):11103-11124.
PMID: 38907711
A hit-to-lead campaign pursuing the identification of novel inhalant small-molecule phosphatidylinositol 3-kinase (PI3K) inhibitors for the treatment of inflammatory respiratory diseases is disclosed. A synthetically versatile pyridazin-3(2)-one scaffold was designed,...
5.
Mazzucato R, Roberti M, Capelli A, Rancati F, Biagetti M, Fiorelli C, et al.
Eur J Med Chem
. 2023 Apr;
254:115331.
PMID: 37094451
PI3Kδ is a lipid kinase which plays a key role in airway inflammatory conditions. Accordingly, the inhibition of PI3Kδ can be considered a valuable strategy for the treatment of chronic...
6.
Armani E, Rizzi A, Iotti N, Saccani F, Di Lascia M, Tigli L, et al.
J Med Chem
. 2023 Apr;
66(8):5622-5656.
PMID: 37017110
Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal disease characterized by lung fibrosis leading to an irreversible decline of lung function. Current antifibrotic drugs on the market slow down...
7.
Ghidini E, Marchini G, Capelli A, Carnini C, Cenacchi V, Fioni A, et al.
J Med Chem
. 2018 May;
61(11):4757-4773.
PMID: 29741897
Inhaled corticosteroids (ICSs) represent the first line therapy for the treatment of asthma and are also extensively utilized in chronic obstructive pulmonary disease. Our goal was to develop a new...
8.
Lodola A, Bertolini S, Biagetti M, Capacchi S, Facchinetti F, Gallo P, et al.
J Med Chem
. 2017 May;
60(10):4304-4315.
PMID: 28489362
IC87114 [compound 1, (2-((6-amino-9H-purin-9-yl)methyl)-5-methyl-3-(o-tolyl)quinazolin-4(3H)-one)] is a potent PI3K inhibitor selective for the δ isoform. As predicted by molecular modeling calculations, rotation around the bond connecting the quinazolin-4(3H)-one nucleus to the...
9.
Callegari D, Lodola A, Pala D, Rivara S, Mor M, Rizzi A, et al.
J Chem Inf Model
. 2017 Feb;
57(2):386.
PMID: 28151658
No abstract available.
10.
Callegari D, Lodola A, Pala D, Rivara S, Mor M, Rizzi A, et al.
J Chem Inf Model
. 2017 Jan;
57(2):159-169.
PMID: 28080056
The duration of drug efficacy in vivo is a key aspect primarily addressed during the lead optimization phase of drug discovery. Hence, the availability of robust computational approaches that can...